The role of progestationally regulated stromal cell tissue factor and type-1 plasminogen activator inhibitor (PAI-1) in endometrial hemostasis and menstruation.
The physiologic mechanisms whereby the human endometrium maintains hemostasis during endovascular trophoblast invasion, yet permits menstrual hemorrhage, are unknown. This paradoxical relationship was investigated by evaluating endometrial expression of tissue factor (TF), the primary initiator of hemostasis, and plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of fibrinolysis. We observed increased immunostaining for TF and PAI-1 in sections of decidualized stromal cells from luteal phase and gestational endometrium. To determine whether TF and PAI-1 expression are directly linked to decidualization, both endpoints were monitored in a well described in vitro model of decidualization. Thus, confluent stromal cell cultures were exposed to vehicle control, 10(-8) M estradiol (E2), 10(-8) to 10(-6) M medroxyprogesterone acetate (MPA) or both E2 + MPA for 2-24 days in serum-containing or defined media. The progestin enhanced the content of stromal cell-associated immunoreactive and functionally active TF and PAI-1 released into the medium and elevated levels of stromal cell TF and PAI-1 mRNA. While E2 alone was ineffective, it greatly augmented MPA-enhanced TF and PAI-1 protein and mRNA content. Dose-dependent effects on TF and PAI-1 content were observed between 10(-8) to 10(-6) M MPA +/- E2. Similar results were observed for decidual cells derived from first trimester endometrium and cultured in type 1 collagen gels. Following optimal induction of TF and PAI-1 expression by E2 + MPA in stromal cell cultures, removal of these steroids greatly reduced levels of both TF and PAI-1 protein and mRNA within 4 days. These studies suggest a mechanism whereby endometrial hemostasis is maintained during trophoblast invasion yet reduced at the end of nonfertile cycles to permit menses.
Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, New York 10029.
C J
CJ
Lockwood
G
G
Krikun
C
C
Papp
E
E
Toth-Pal
L
L
Markiewicz
E Y
EY
Wang
T
T
Kerenyi
X
X
Zhou
V
V
Hausknecht
Z
Z
Papp
D002478:Cells, Cultured; D003656:Decidua / Q000502:physiology; D004717:Endometrium / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006487:Hemostasis; D006801:Humans; D007150:Immunohistochemistry; D008183:Luteal Phase; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology; D008598:Menstruation / Q000502:physiology*; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000235:genetics / Q000502:physiology*; D011247:Pregnancy; D011374:Progesterone / Q000502:physiology*; D012333:RNA, Messenger / Q000378:metabolism; D013925:Thromboplastin / Q000032:analysis / Q000235:genetics / Q000502:physiology*
D017395:Plasminogen Activator Inhibitor 1; D012333:RNA, Messenger; D011374:Progesterone; D013925:Thromboplastin; D017258:Medroxyprogesterone Acetate